Bray Capital Advisors’s GSK GSK Stock Holding History

Bray Capital Advisors’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-348	Closed	-$10K	–	280
2022 Q3	$10K	Hold	348	–	–	﹤0.01%	257
2022 Q2	$19K	Hold	348	–	–	0.01%	226
2022 Q1	$19K	Hold	348	–	–	﹤0.01%	232
2021 Q4	$19K	Hold	348	–	–	﹤0.01%	235
2021 Q3	$17K	Hold	348	–	–	﹤0.01%	234
2021 Q2	$17K	Hold	348	–	–	﹤0.01%	231
2021 Q1	$16K	Hold	348	–	–	﹤0.01%	234
2020 Q4	$16K	Hold	348	–	–	﹤0.01%	234
2020 Q3	$16K	Hold	348	–	–	0.01%	223
2020 Q2	$18K	Hold	348	–	–	0.01%	217
2020 Q1	$16K	Hold	348	–	–	0.01%	216
2019 Q4	$20K	Hold	348	–	–	0.01%	222
2019 Q3	$19K	Hold	348	–	–	0.01%	226
2019 Q2	$17K	Hold	348	–	–	0.01%	242
2019 Q1	$18K	Hold	348	–	–	0.01%	235
2018 Q4	$17K	Hold	348	–	–	0.01%	238
2018 Q3	$17K	Hold	348	–	–	0.01%	243
2018 Q2	$18K	Buy	+348	New	+$17.5K	0.01%	291
2015 Q3	–	Sell	-4,095	Closed	-$213K	–	407
2015 Q2	$213K	Hold	4,095	–	–	0.12%	126
2015 Q1	$236K	Sell	4,095 -880	-18%	-$50.5K	0.14%	126
2014 Q4	$266K	Buy	+4,975	New	+$278K	0.17%	122

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

AWA

Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Bray Capital Advisors's GSK Position: Q4 2022 in Review

Bray Capital Advisors sold out of GSK (GSK) in Q4 2022, closing a stake of 348 shares — an estimated $10K sold.

Bray Capital Advisors first reported a position in GSK in Q4 2014 and held it in 21 quarters. The position peaked at $266K in Q4 2014. 813 funds tracked by Wall St. Rank hold GSK as of Q4 2022.

Bray Capital Advisors reported no remaining GSK position as of Q4 2022 after selling out during the quarter.
Bray Capital Advisors sold 348 GSK shares in Q4 2022, an estimated $10K.
Bray Capital Advisors first reported a position in GSK in Q4 2014 and held it in 21 quarters.
Bray Capital Advisors's GSK position peaked at $266K in Q4 2014.
813 funds tracked by Wall St. Rank held GSK as of Q4 2022.

Based on Bray Capital Advisors's 13F filing for Q4 2022, filed 20 Jan 2023.